LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein.

    Iliopoulou, Konstantina / Koufargyris, Panagiotis / Doulou, Sarantia / Tasouli, Elisavet / Katopodis, Sokratis / Chachali, Stavroula-Porphyria / Schinas, Georgios / Karachalios, Charalampos / Astriti, Myrto / Katsaounou, Paraskevi / Chrysos, George / Seferlis, Theodoros / Dimopoulou, Effrosyni / Kollia, Myrto / Poulakou, Garyphalia / Gerakari, Styliani / Papanikolaou, Ilias C / Milionis, Haralampos / Dalekos, George N /
    Tzavara, Vasiliki / Kontopoulou, Theano / Giamarellos-Bourboulis, Evangelos J

    Infectious diseases and therapy

    2023  Volume 13, Issue 1, Page(s) 105–119

    Abstract: Introduction: The aim was to assess the performance of a blood assay combining measurements of MxA (myxovirus resistance protein A) and CRP (C-reactive protein) to differentiate viral from bacterial respiratory infections.: Methods: In a prospective ... ...

    Abstract Introduction: The aim was to assess the performance of a blood assay combining measurements of MxA (myxovirus resistance protein A) and CRP (C-reactive protein) to differentiate viral from bacterial respiratory infections.
    Methods: In a prospective study, MxA and CRP were measured in the blood by the AFIAS panel in adults admitted with respiratory infection. Patients were split into discovery and validation cohorts. Final diagnosis was adjudicated by a panel of experts. Microbiology-confirmed cases comprised the discovery cohort, and infections adjudicated as highly probable viral or bacterial comprised the validation cohort.
    Results: A total of 537 patients were analyzed: 136 patients were adjudicated with definitive viral infections and 131 patients with definitive bacterial infections. Using logistic regression analysis, an equation was developed to calculate the probability for bacterial infection using the absolute value of MxA and CRP. Calculated probability ≥ 0.5 and/or MxA to CRP ratio less than 2 applied as the diagnostic rule for bacterial infections. This rule provided 91.6% sensitivity and 90.4% negative predictive value for the diagnosis of bacterial infections. This diagnostic sensitivity was confirmed in the validation cohort. A MxA/CRP ratio less than 0.15 was associated with unfavorable outcome.
    Conclusion: The calculation of the probability for bacterial infection using MxA and CRP may efficiently discriminate between viral and bacterial respiratory infections.
    Language English
    Publishing date 2023-12-19
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2701611-0
    ISSN 2193-6382 ; 2193-8229
    ISSN (online) 2193-6382
    ISSN 2193-8229
    DOI 10.1007/s40121-023-00901-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial.

    Giamarellos-Bourboulis, Evangelos J / Siampanos, Athanasios / Bolanou, Amalia / Doulou, Sarantia / Kakavoulis, Nikolaos / Tsiakos, Konstantinos / Katopodis, Sokratis / Schinas, Georgios / Skorda, Lamprini / Alexiou, Zoi / Armenis, Konstantinos / Katsaounou, Paraskevi / Chrysos, George / Masgala, Aikaterini / Poulakou, Garyphalia / Antonakos, Nikolaos / Safarika, Asimina / Kyprianou, Miltiades / Dakou, Konstantina /
    Gerakari, Styliani / Papanikolaou, Ilias C / Milionis, Haralampos / Marangos, Markos / Dalekos, George N / Tzavara, Vasiliki / Akinosoglou, Karolina / Hatziaggelaki, Eryfilli / Sympardi, Styliani / Kontopoulou, Theano / Mouktaroudi, Maria / Papadopoulos, Antonios / Niederman, Michael S

    The Lancet. Respiratory medicine

    2024  Volume 12, Issue 4, Page(s) 294–304

    Abstract: Background: Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials. We ...

    Abstract Background: Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials. We investigated if addition of the macrolide clarithromycin to treatment with a β-lactam antibiotic in this population could improve early clinical response-the new regulatory endpoint for community-acquired pneumonia-and explored the possible contribution of modulation of the inflammatory host response to that outcome.
    Methods: The ACCESS trial was a phase 3 prospective, double-blind, randomised controlled trial, in which adults in hospital with community-acquired pneumonia who had systemic inflammatory response syndrome, Sequential Organ Failure Assessment (SOFA) score of 2 or more, and procalcitonin 0·25 ng/mL or more were enrolled in 18 internal medicine departments of public Greek hospitals. Patients were randomly assigned (1:1) by computer-generated block randomisation to standard of care medication (including intravenous administration of a third-generation cephalosporin or intravenous administration of β-lactam plus β-lactamase inhibitor combination) plus either oral placebo or oral clarithromycin 500 mg twice daily for 7 days. Investigators, staff, and patients were masked to group allocation. The primary composite endpoint required that patients fulfilled both of the following conditions after 72 hours (ie, day 4 of treatment): (1) decrease in respiratory symptom severity score of 50% or more as an indicator of early clinical response and (2) decrease in SOFA score of at least 30% or favourable procalcitonin kinetics (defined as ≥80% decrease from baseline or procalcitonin <0·25 ng/mL), or both, as an indicator of early inflammatory response. Participants who were randomly assigned and received allocated treatment were included in the primary analysis population. This trial is complete and is registered with the EU Clinical Trials Register (2020-004452-15) and ClinicalTrials.gov (NCT04724044).
    Findings: Patients were enrolled between Jan 25, 2021, and April 11, 2023, and 278 individuals were randomly allocated to receive standard of care in combination with either clarithromycin (n=139) or placebo (n=139). 134 patients in the clarithromycin group (five withdrew consent) and 133 patients in the placebo group (six withdrew consent) were included in the analysis of the primary endpoint. The primary endpoint was met in 91 (68%) patients in the clarithromycin group and 51 (38%) patients in the placebo group (difference 29·6% [95% CI 17·7-40·3]; odds ratio [OR] 3·40 [95% CI 2·06-5·63]; p<0·0001). Serious treatment-emergent adverse events (TEAEs) occurred in 58 (43%) patients in the clarithromycin group and 70 (53%) patients in the placebo group (difference 9·4% [95% CI -2·6 to 20·9]; OR 0·67 [95% CI 0·42 to 1·11]; p=0·14). None of the serious TEAEs was judged to be related to treatment assignment.
    Interpretation: Addition of clarithromycin to standard of care enhances early clinical response and attenuates the inflammatory burden of community-acquired pneumonia. The mechanism of benefit is associated with changes in the immune response. These findings suggest the importance of adding clarithromycin to β-lactams for treatment of patients in hospital with community-acquired pneumonia to achieve early clinical response and early decrease of the inflammatory burden.
    Funding: Hellenic Institute for the Study of Sepsis and Abbott Products Operations.
    MeSH term(s) Adult ; Humans ; Clarithromycin/therapeutic use ; Greece ; Prospective Studies ; Procalcitonin ; Pneumonia/drug therapy ; Anti-Bacterial Agents ; Anti-Inflammatory Agents ; Double-Blind Method ; Treatment Outcome
    Chemical Substances Clarithromycin (H1250JIK0A) ; Procalcitonin ; Anti-Bacterial Agents ; Anti-Inflammatory Agents
    Language English
    Publishing date 2024-01-03
    Publishing country England
    Document type Randomized Controlled Trial ; Clinical Trial, Phase III ; Journal Article
    ZDB-ID 2686754-0
    ISSN 2213-2619 ; 2213-2600
    ISSN (online) 2213-2619
    ISSN 2213-2600
    DOI 10.1016/S2213-2600(23)00412-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7041: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: A novel optical biosensor for the early diagnosis of sepsis and severe Covid-19: the PROUD study.

    Doulou, Sarantia / Leventogiannis, Konstantinos / Tsilika, Maria / Rodencal, Matthew / Katrini, Konstantina / Antonakos, Nikolaos / Kyprianou, Miltiades / Karofylakis, Emmanouil / Karageorgos, Athanassios / Koufargyris, Panagiotis / Christopoulos, Gennaios / Kassianidis, George / Stamatelopoulos, Kimon / Newberry, Robert / Giamarellos-Bourboulis, Evangelos J

    BMC infectious diseases

    2020  Volume 20, Issue 1, Page(s) 860

    Abstract: Background: The accuracy of a new optical biosensor (OB) point-of-care device for the detection of severe infections is studied.: Methods: The OB emits different wavelengths and outputs information associated with heart rate, pulse oximetry, levels ... ...

    Abstract Background: The accuracy of a new optical biosensor (OB) point-of-care device for the detection of severe infections is studied.
    Methods: The OB emits different wavelengths and outputs information associated with heart rate, pulse oximetry, levels of nitric oxide and kidney function. At the first phase, recordings were done every two hours for three consecutive days after hospital admission in 142 patients at high-risk for sepsis by placing the OB on the forefinger. At the second phase, single recordings were done in 54 patients with symptoms of viral infection; 38 were diagnosed with COVID-19.
    Results: At the first phase, the cutoff value of positive likelihood of 18 provided 100% specificity and 100% positive predictive value for the diagnosis of sepsis. These were 87.5 and 91.7% respectively at the second phase. OB diagnosed severe COVID-19 with 83.3% sensitivity and 87.5% negative predictive value.
    Conclusions: The studied OB seems valuable for the discrimination of infection severity.
    MeSH term(s) Aged ; Aged, 80 and over ; Algorithms ; Area Under Curve ; Betacoronavirus/isolation & purification ; Biosensing Techniques/methods ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Coronavirus Infections/diagnosis ; Coronavirus Infections/pathology ; Coronavirus Infections/virology ; Early Diagnosis ; Female ; Humans ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/pathology ; Pneumonia, Viral/virology ; ROC Curve ; SARS-CoV-2 ; Sensitivity and Specificity ; Sepsis/diagnosis ; Severity of Illness Index
    Keywords covid19
    Language English
    Publishing date 2020-11-19
    Publishing country England
    Document type Journal Article
    ISSN 1471-2334
    ISSN (online) 1471-2334
    DOI 10.1186/s12879-020-05607-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients

    Ulas, Thomas / Seep, Lea / Schulte-Schrepping, Jona / De Domenico, Elena / Mengiste, Simachew / Theis, Heidi / Kraut, Michael / Becker, Matthias / Gierlich, Jannik / Lenkeit, Lena / Drews, Anna / van Uelft, Martina / Dahm, Kilian / Agrawal, Shobhit / Gemuend, Ioanna D / Horne, Arik / Holsten, Lisa / Herbert, Miriam / Kroeger, Charlotte /
    Kapellos, Theodorw S / Pecht, Tal / Knoll, Rainer / Bassler, Kevin / Reusch, Nico / Bonaguro, Lorenzo / Nuesch-Germano, Melanie / Oestreich, Marie / Aschenbrenner, Anna Christin / Schultze, Joachim L / Kox, Matthijs / Bruse, Niklas / Pickkers, Peter / Gerretsen, Jelle / Netea, Mihai. G / van de Veerdonk, Frank / Nattermann, Jacob / Kraemer, Benjamin / Raabe, Jan / ToVinh, Michael / Hoffmeister, Christoph / Rieke, Gereon J / Keitel, Verena / Breteler, Monique MB / Aziz, Ahmad N / Talevi, Valentina / Giamarellos-Bourboulis, Evangelos J / Mouktaroudi, Maria / Antonakos, Nikolaos / Gkizeli, Konstantina / Saridaki, Maria / Doulou, Sarantia / Rovina, Nikoletta / Koutsoukou, Antonia

    medRxiv

    Abstract: The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, ... ...

    Abstract The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in the severe cases calls for a better characterization and understanding of the changes in the immune system. Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated signatures were prominently enriched in severe patient groups, which was corroborated in whole blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third cohort of 11 COVID-19 patients. Comparison of COVID-19 blood transcriptomes with those of a collection of over 2,600 samples derived from 11 different viral infections, inflammatory diseases and independent control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic immune response of the host.
    Keywords covid19
    Language English
    Publishing date 2020-07-08
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2020.07.07.20148395
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top